ContributorsPublishersAdvertisers

Study: Immunotherapy Results in Longer Treatment-Free Survival Than Targeted Therapy in Patients With Renal Cell Carcinoma

pharmacytimes.com
 2021-11-24

Cover picture for the articlePatients with advanced renal cell carcinoma who were given the combination of nivolumab and ipilimumab demonstrated a significantly longer overall survival than those who received sunitinib. The combination therapy of nivolumab plus ipilimumab resulted in longer treatment-free survival (TFS) over a 42-month period compared to the targeted therapy sunitinib...

www.pharmacytimes.com

Comments / 0

Comments / 0